Navigation Links
New study shows why swine flu virus develops drug resistance
Date:5/29/2012

Professor Adrian Mulholland and Dr Christopher Woods from Bristol's School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza commonly known as 'swine flu'.

Their results, published today [29 May] in Biochemistry, provide new insight that could lead to the development of the next generation of antiviral treatments for flu.

H1N1-2009 is a new, highly adaptive virus derived from different gene segments of swine, avian, and human influenza. Within a few months of its appearance in early 2009, the H1N1-2009 strain caused the first flu pandemic of the 21st-century.

The antiviral drugs Relenza and Tamiflu, which target the neuraminidase (NA) enzyme, successfully treated the infection but widespread use of these drugs has led to a series of mutations in NA that reduce the drugs' effectiveness.

Clinical studies indicate that the double mutant of swine flu NA known as IRHY2 reduced the effectiveness of Relenza by 21 times and Tamiflu by 12,374 times that is, to the point where it has become an ineffective treatment.

To understand why the effectiveness of Relenza and Tamiflu is so seriously reduced by the occurrence of this mutation, the researchers performed long-timescale molecular dynamics (MD) simulations using GPUs.

Professor Mulholland said: "Our simulations showed that IRHY became resistant to Tamiflu due to the loss of key hydrogen bonds between the drug and residues in a part of the NA's structure known as the '150-loop'.

"This allowed NA to change from a closed to an open conformation. Tamiflu binds weakly with the open conformation due to poor electrostatic interactions between the drug and the active site, thus rendering the drug ineffective."

These findings suggest that drug resistance could be overcome by increasing hydrogen bond interactions between NA inhibitors and residues in the 150-loop, with the aim of maintaining the closed conformation.


'/>"/>

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
University of Bristol
Source:Eurekalert

Related medicine news :

1. STeleR study: Telerehab improves functioning after stroke
2. Night Shift Might Boost Womens Breast Cancer Risk: Study
3. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
4. As Obesity Rates Rise, Cases of Kidney Stones Double: Study
5. Physical Education Is Good for Kids Grades, Study Finds
6. New prostate cancer screening guidelines face a tough sell, study suggests
7. Chemicals in PVC Flooring Can Be Absorbed Into Childrens Bodies: Study
8. First study to suggest that the immune system may protect against Alzheimers changes in humans
9. States Use Only Fraction of Tobacco Revenues to Fight Smoking, Study Finds
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. Surgical Residents Often Fatigued, Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today announced ... Pfizer Inc. and President of Pfizer Global Supply, has been ... February 4, 2016. In addition, the Company announced that Mr. ... audit committee since 2010, has retired from the AMRI Board ... to his other business ventures.  William S. ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology: